Contact:
PRISM BioLab Co., Ltd.
info@prismbiolab.com

26-1, Muraoka-Higashi 2-chome. Fujisawa,
Kanagawa 251-8555
https://prismbiolab.com

PRESS RELEASE

Notice of Expiration of the Library Screening and License Agreement with Merck Healthcare KGaA

TOKYO, Japan, November 13, 2026: -- PRISM BioLab, Co., Ltd. ("PRISM") hereby announces that the library screening and license agreement (the "Agreement") between PRISM and Merck Healthcare KGaA ("Merck") will expire upon the completion of its contractual term, as outlined below.

PRISM and Merck entered into the Agreement on October 12, 2020. Under the Agreement, PRISM provided its PepMetics® library for the purpose of screening against Merck's drug discovery targets and conducted research and development activities related to identified hit compounds. PRISM has also received payments from Merck for the use of such compounds.

Following discussions between the parties regarding the future of the Agreement after the expiration of the screening period thereunder, the parties mutually agreed to terminate the Agreement effective November 13, 2026.

No additional financial obligations will arise in connection with the expiration of the Agreement, and the expiration is not expected to have any impact on PRISM's financial results for the current fiscal year.

Sincerely,
PRISM BioLab Co., Ltd.